37 results about "Anxiety disorder" patented technology

The application provides an application of a motion-induced sweat extract in preparation of a medicine for treating, relieving or preventing depression and / or anxiety, and belongs to the field of biological medicine. Specifically, sweat is induced by making a healthy subject perform aerobic exercise of a specific intensity (such as 60%-80% of maximum heart rate), the sweat is collected and eluted by physiological saline, centrifuged and filtered to obtain a biologically active sweat extract. The extract is analyzed by transcriptomics and reverse transcription method to predict the anti-depression potential, and it is proved by in-vivo animal experiments that the extract can significantly improve the anhedonia, behavioral despair and anxiety-like behavior of a depression model mouse, and the effect of a high dose is equivalent to that of a first-line drug fluoxetine. The preparation raw material provided by the application is natural and safe, the preparation process is simple and the cost is low, and a new, easy-to-promote alternative strategy is provided for the prevention and treatment of depression.

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

The application provides application of dimethyl itaconate in prevention and treatment of chronic stress-induced anxiety. The application finds that dimethyl itaconate can inhibit excessive activation of microglial cells in a stress state, improve mitochondrial structure and function abnormalities of the microglial cells, and reduce expression of a lysosome marker CD68, so as to inhibit central nervous inflammation, maintain central nervous immune homeostasis, prevent and relieve anxiety-like behavior induced by chronic stress, and effectively prevent and relieve occurrence and development of chronic stress-induced anxiety (generalized anxiety disorder).

We provide TRPC5 inhibitors for use in treating or reducing the risk of developing kidney disease, diabetic retinopathy, anxiety disorders, depression, or cancer. [Solution] Compounds according to formula (I) or (II), and pharmaceutical compositions containing them are disclosed. A therapeutic method using a compound of formula (I) or (II) to treat, for example, kidney disease is also disclosed. JPEG2026086459000081.jpg3992

Methods of using a pharmaceutical composition comprising ebastine and alprazolam for treating patients suffering from one or more psychiatric disorders, such as major depressive disorder, generalized anxiety disorder, mild chronic depression, premenstrual dysphoric disorder are disclosed.

This invention belongs to the field of biomedicine and discloses estradiol derivatives or pharmaceutically acceptable salts thereof with the structure shown in Formula I: R is selected from R1, which is selected from F, Cl, Br, and I; L is selected from straight-chain or branched alkyl groups with 2 to 10 carbon atoms. This invention also discloses the use of the estradiol derivatives or pharmaceutically acceptable salts thereof in the preparation of drugs for treating depression and anxiety. Furthermore, this invention discloses the use of the estradiol derivatives or pharmaceutically acceptable salts thereof in the preparation of drugs targeting ERβ / SERT for treating depression and anxiety. The estradiol derivatives of this invention can simultaneously and effectively inhibit SERT and activate ERβ, thereby synergistically enhancing serotonergic neurotransmission and regulating neuroplasticity, and enhancing antidepressant efficacy through multi-target synergistic effects.

The application belongs to the technical field of medicines, and relates to an N-H aporphine nitrogen-containing heterocyclic derivative, a preparation method and application thereof.The N-H aporphine nitrogen-containing heterocyclic derivative comprises a compound shown in a general formula M, isomers thereof and pharmaceutically acceptable salts or hydrates thereof.The application introduces a nitrogen-containing heterocyclic ring into an aporphine derivative, and the disclosed N-H aporphine nitrogen-containing heterocyclic derivative can be applied in the preparation of medicines for preventing and / or treating obesity, urinary incontinence, depression, anxiety, obsessive-compulsive disorder, epilepsy, schizophrenia, pain, diabetes and drug addiction.

Provided are a polypeptide and a use thereof. Provided is a use of a polypeptide in preparation of a medication for treating and / or preventing PTSD, depression, or anxiety disorder, thereby providing a treatment strategy for PTSD, depression, or anxiety disorder. Provided are a polypeptide, a complex, a nucleic acid molecule, an expression vector, and a host cell.

Methods and systems for improving medical conditions by delivering a focused ultrasound signal to target sites of the brain. The focused ultrasound signal can have a mechanical index of between about 1.0 to about 8.0 and / or an acoustic pressure of between about 1.0 MPa to about 3.0 MPa. The medical condition can comprise addiction (including binge eating), anxiety disorders and anxiety associated disorders, tinnitus, neurodegenerative disorders, neuropsychiatric disorders, cognitive disorders, neurodevelopmental disorders, post-traumatic stress disorder, stroke recovery, and combinations thereof.

This invention discloses a novel class of monoacylglycerol lipase (MAGL) small molecule inhibitors, as well as their pharmaceutically acceptable compositions, methods of preparation, and uses. The MAGL small molecule inhibitors are represented by formula (I), having the specific substituents and definitions described herein. The disclosed MAGL small molecule inhibitors exhibit excellent MAGL enzyme inhibitory activity. This invention includes these compounds or their pharmaceutically acceptable compositions for the treatment and / or prevention of MAGL-related conditions such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colorectal cancer lesions, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain, and / or pain-related spasticity.

The application belongs to the technical field of biological medicine, and specifically discloses a kind of Exosc9 The application discloses application of a gene mutation animal in construction of an anxiety model and in screening of an anti-anxiety drug. Exosc9 The gene mutation animal is a known model, but the application finds that the animal shows behavior phenotypes related to anxiety through systematic behavior experiments, including a decrease in central zone activity in an open field experiment, a decrease in open arm staying time in a high cross maze experiment, and a decrease in exploration behavior. Through behavior observation and quantitative analysis of the animal, the application can be used to study behavior characteristics of anxiety, compare phenotype differences of animals of different genotypes, genders and ages, and analyze influences of genetic and environmental factors on anxiety behavior. The application also constructs a method for screening of an anti-anxiety candidate drug and evaluation of drug efficacy based on the model, which can greatly shorten an early screening period of drug research and development, and has a wide application prospect in the field of neuropsychiatric disease research and drug research and development.

The present disclosure relates to methods of treating major depressive disorder (MDD) with elevated anxiety in a subject in need thereof, by administering a therapeutically effective amount of Compound (1), or a pharmaceutically acceptable salt thereof. The disclosure also relates to methods of treating postpartum depression (PPD) with elevated anxiety in a subject in need thereof, by administering a therapeutically effective amount of Compound (1), or a pharmaceutically acceptable salt thereof.

The application provides a lactobacillus plantarum HLP0107 and application of the strain or a fermentation product thereof in preventing and / or improving depression and anxiety.

This invention provides a traditional Chinese medicine composition for treating anxiety, depression, and / or sleep disorders, its preparation method, and its application, belonging to the field of traditional Chinese medicine technology. The traditional Chinese medicine composition includes the following raw materials: *Aconitum carmichaelii* root slices, calcined magnetite, stir-fried jujube seed, prepared polygala tenuifolia root, prepared pinellia tuber, tangerine peel, stir-fried immature bitter orange, ginger-processed bamboo shavings, albizia bark, poria cocos, coix seed, bamboo leaf bupleurum root, oyster shell, licorice root, and dragon bone. The preparation method includes: first decocting the *Aconitum carmichaelii* root slices, then adding the remaining medicinal ingredients and decocting with water; concentrating the filtrate into a clear paste, adding excipients, and compressing into tablets. Animal experiments show that, compared with the model group, the traditional Chinese medicine composition of this invention can significantly increase the number of times mice enter the central region and the dwell time in the open field test, and improve the number of times mice enter the open arms of the elevated cruciate maze and the dwell time; hippocampal Nielsen staining shows that neurons are neatly arranged and cell density is well restored. This invention has the effects of warming the kidney and suppressing yang, resolving phlegm and calming the mind, and can be used to prepare drugs for treating anxiety, depression, and / or sleep disorders.

This invention discloses the application of prostaglandin A2 in the preparation of drugs for treating anxiety disorders and the related pharmaceutical formulation. It belongs to the field of biomedical technology, and specifically relates to the application of prostaglandin A2 in the preparation of drugs for treating anxiety disorders. Through chronic restraint stress (CRS) mouse models, corticosterone-induced (CORT)-damaged PC12 cell models, and multi-level molecular, circuit, and behavioral analyses, this invention demonstrates that prostaglandin A2 can exert multi-target anti-anxiety effects at the levels of overall behavior, cellular function, neural circuit structure, and molecularity. Prostaglandin A2 can treat anxiety disorders by improving anxiety-like behaviors and reversing behavioral phenotypic damage.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of N-methyltyramine in the preparation of drugs for improving anger and irritability. The CAS number of the N-methyltyramine (NMT) is 370-98-9. Experimental results show that NMT can directly target and positively regulate the γ-aminobutyric acid type A receptor (GABA). a NMT activates the downstream AC5-cAMP-PKA signaling pathway, thereby improving abnormal emotional states such as anger and depression. Through network pharmacology, molecular docking, micro-thermophoresis experiments, animal behavioral experiments, and cell experiments, NMT significantly improves the behavior of model animals. Therefore, this invention reveals for the first time that NMT improves abnormal emotional states such as anger and depression through GABA. a The mechanism by which R-related signaling pathways play a role in mood regulation can be used to prepare drugs for treating mood disorders such as anxiety, depression, and post-traumatic stress disorder, and has good application prospects.

The disclosure provides methods for the acute treatment of depression and / or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A or 5-HT2A / D2 receptor ligand, e.g. lumateperone.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The application discloses a composition of GLP-1 and PYY 3‑36 polypeptide analogues and a preparation method and application thereof, and relates to the technical field of biological medicines. The composition comprises: a GLP-1 polypeptide analogue and a PYY 3‑36 polypeptide analogue. Compared with GLP-1 natural sequences and PYY 3‑36 natural sequences, the composition of the GLP-1 polypeptide analogue and the PYY 3‑36 polypeptide analogue has remarkable effects on improving metabolic diseases such as obesity, diabetes and fatty liver and emotional diseases such as anxiety and depression.

The present invention relates to novel lactic acid bacteria, Lactococcus lactis P32 (KCCM13222P), Bifidobacterium bifidum P45 (KCCM13223P), or a mixture thereof, and uses thereof. Strains and a mixture thereof, according to the present invention, can be effectively used in the prevention or treatment of an inflammatory disease, osteoporosis, depressive disorder, or anxiety disorder.

Disclosed herein are aldehyde dehydrogenase (ALDH-2) inhibitor compounds, such as a compounds of Formula (I) or Formula (II), pharmaceutical compositions comprising these inhibitor compounds, and uses of these compounds and compositions, such as in the methods for safely treating chemical dependency on a substance or condition of addiction, such as alcohol, nicotine, cocaine, opiates, amphetamines, and compulsive eating disorder, and / or anxiety disorder, each individually or concurrent.

The application belongs to the technical field of biological medicine, and specifically discloses a kind of Exosc9 The application discloses application of a gene mutation animal in construction of an anxiety model and in screening of an anti-anxiety drug. Exosc9 The gene mutation animal is a known model, but the application finds that the animal shows behavior phenotypes related to anxiety through systematic behavior experiments, including a decrease in central zone activity in an open field experiment, a decrease in open arm staying time in a high cross maze experiment, and a decrease in exploration behavior. Through behavior observation and quantitative analysis of the animal, the application can be used to study behavior characteristics of anxiety, compare phenotype differences of animals of different genotypes, genders and ages, and analyze influences of genetic and environmental factors on anxiety behavior. The application also constructs a method for screening of an anti-anxiety candidate drug and evaluation of drug efficacy based on the model, which can greatly shorten an early screening period of drug research and development, and has a wide application prospect in the field of neuropsychiatric disease research and drug research and development.

Disclosed in the present invention is a 1-thienyl-β-carboline-based IDO1 and TDO dual inhibitor, selected from a 1-thienyl-β-carboline derivative having a structure as represented by formula I or a pharmaceutically acceptable salt thereof. R1 is hydrogen, fluorine, chlorine or bromine, R2 is hydrogen, methyl or trifluoromethyl, R3 is methyl, and R4 is C1-C4 linear or branched alkyl. Disclosed in the present invention is a use of the 1-thienyl-β-carboline derivative or the pharmaceutically acceptable salt thereof in the preparation of a IDO1 and TDO dual inhibitor. Disclosed in the present invention is a use of the 1-thienyl-β-carboline derivative or the pharmaceutically acceptable salt thereof in the preparation of a medicament for treating IDO1- and TDO-mediated diseases. The IDO1- and TDO-mediated diseases are central nervous system diseases associated with IDO1- and TDO-mediated tryptophan-kynurenine metabolic pathway abnormalities, specifically including depression, anxiety, Parkinson's disease and Alzheimer's disease.

The application belongs to the field of anxiety prevention and treatment, and particularly relates to application of Kynu gene or kynureninease KYNU as an anxiety treatment target. The Kynu gene or its encoded protein kynureninease can be used as a target to prevent, alleviate and / or treat anxiety, and an inhibitor of the Kynu gene or its encoded protein kynureninease KYNU can be used to prepare or screen a drug for preventing, alleviating and / or treating anxiety. The application explains the interaction between the kynureninease protein KYNU and anxiety, and through inhibition of Kynu gene expression, the correlation between KYNU and anxiety is determined, that is, inhibition of KYNU expression can effectively prevent, alleviate and / or treat anxiety, thereby providing a new research idea and direction for clinical treatment of anxiety.

The present invention relates a method of treating attention-deficit / hyperactivity disorder (ADHD), wherein the patient suffers from mood disorders and / or anxiety. More specifically, the present invention is directed to a method of using a carbamate compound alone or in combination with other medications, for the treatment of ADHD.

The present invention relates to a composition for preventing, alleviating, or treating depression or anxiety disorder, the composition comprising a zeolite as an active ingredient, wherein the zeolite is excellent in increasing activity by alleviating depression or anxiety disorder in open-field tests and light-dark tests using a colitis animal model induced by dextran sulfate sodium salt (DSS), and is thus expected to be useful as a composition for preventing, alleviating, or treating depression or anxiety disorder.

The present application relates to the technical field of medical devices and neuromodulation, and discloses an anxiety disorder transcranial electrical stimulation intervention system and method based on functional magnetic resonance, which comprises: a brain function image analysis module, which is used for acquiring functional magnetic resonance imaging data of a subject when performing a threatening stimulus attention bias task, extracting BOLD time series of the dorsolateral prefrontal cortex and the amygdala, calculating effective connection strength values from the dorsolateral prefrontal cortex to the amygdala, functional connection values between the dorsolateral prefrontal cortex and the amygdala, recording behavioral response time indicators of the subject to the threatening stimulus, and generating an individualized stimulation scheme according to the above three indicators through a dynamic grading control algorithm; a transcranial direct current stimulation intervention module, which applies electrical stimulation to the target brain area according to the individualized stimulation scheme; and a central control and data processing module, which is connected with the above two modules respectively and is used for coordinating the work flow. The present application improves the accuracy and individualization level of intervention.

The application discloses a traditional Chinese medicine composition and application thereof in preparation of a medicine for treating anxiety symptoms and / or depression symptoms of a vascular dementia patient, and relates to the technical field of traditional Chinese medicine preparation. The traditional Chinese medicine composition in the application has the function of nourishing blood and tranquilizing the mind, and the medicine developed by combining the traditional Chinese medicine composition with a brain metabolism medicine component has obvious improvement effect on the treatment of anxiety symptoms and depression symptoms of the vascular dementia patient, can preferably improve the healthy qi to stabilize the mood, promote blood circulation to relieve the anxiety symptoms and depression symptoms of the vascular dementia patient, is beneficial to the improvement of the mental state of the patient, and will not cause harmful side effects.

The present disclosure generally relates to probiotics for reducing pro-inflammatory cytokine release. In particular, the present disclosure provides compositions comprising Lactobacillus rhamnosus GG and Bifidobacterium animalis lactis that can reduce overall pro-inflammatory cytokines, such as, for example, interleukin-6 (IL-6) in a subject. The present disclosure provides a method for preventing, reducing, or ameliorating stress and / or anxiety symptoms in a subject in need thereof with a composition comprising Lactobacillus rhamnosus GG and Bifidobacterium animalis lactis.